Drug Discovery – R&D
CENTOGENE provides companies with tools to accelerate drug discovery. From population screening studies that elucidate the prevalence of a rare disease to disease modeling, we are your partner in de-risking drug development for rare diseases.
Advancing Target Discovery to Develop New Therapies for Rare Diseases
CENTOGENE provides companies with tools and services to accelerate early drug discovery. From population screening studies that elucidate the prevalence of a rare disease, to in-vitro disease modeling, to biomarker investigation, to drug target identification, we are your partner in de-risking early drug development for rare diseases.
CENTOGENE is leveraging our multi-pronged method to diagnose, understand, and treat rare diseases to deliver compounding, exponential results and drive value creation.
We help accelerate and de-risk drug discovery alongside our partners, such as Pfizer:
In 2019, we announced a new data access and collaboration agreement with Pfizer Inc. (NYSE: PFE). The agreement grants Pfizer access to CENTOGENE’s Bio/Databank, which may be used to discover and validate novel genetic and biochemical targets and potentially develop new therapies for rare diseases.
Under the terms of the agreement, CENTOGENE and Pfizer will work together to analyze data and jointly agree to collaborate on research projects to substantiate results of data mining.
CENTOGENE’s unique Bio/Databank integrates relevant structured and unstructured patient-consented data, including clinical information, health records, and multiomic data, including genetic, transcriptomic, proteomic, and metabolomic insights. It also includes longitudinal data, such as biomarkers and patient outcomes, as well as diagnostic workflow data. Individual-level data is managed, protected, and shared in compliance with international data privacy regulations.
CENTOGENE Is on a Mission To Enable the Cure of 100 Rare Diseases Within the Next 10 Years.
We are currently focusing our efforts on three priority diseases:
Gaucher disease (GD) is among the most prevalent, recessively inherited, lysosomal storage disorders (LSDs). It is caused by a deficiency in the enzyme β-glucocerebrosidase.
Niemann-Pick Type C Disease
Niemann-Pick disease type C (NPC) is a slow-progressing, autosomal recessive disorder in which the primary hallmark is accumulation of lipids in lysosomes. Symptoms are age dependent.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting approximately 2% of the population over 60 years of age. Onset before age 21 is referred to as juvenile-onset PD.
Our Other Services
By leveraging our proprietary Bio/Databank, multiomic platform and extensive network of physicians, we can help de-risk orphan drug development for our partners by seamlessly and quickly identifying and/or stratifying patients recruited into clinical trials.
Clinical Trial Support
We provide a broad range of services to successfully operate clinical trials. We leverage our proprietary Bio/Databank, multiomic platform, extensive physician network and our experts to ensure efficient and effective solutions to drive progress in the rare disease space.